HROW News and Press, Harrow Health Inc.

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...

Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...

2024-07-02 11:52:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Harrow (NASDAQ: HROW ) just reported results for the second quarter of 2023. Harrow reported earnings per share of -2 cents. This was above the analyst estimate for EPS of...

2024-06-24 23:37:45 ET Summary B. Riley Bonds offer highest reward to risk ratio. CoreCivic's senior bond replaces SLM Corporation's in high yield recommendations. Recommended high yield bonds offer higher returns with lower risk than high yield bond funds. B. Riley ...

2024-06-24 11:42:34 ET Summary Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in $1.50 of incremental FCF/share in 2025, and then ...

2024-06-21 10:00:07 ET Chase Knickerbocker from Craig-Hallum issued a price target of $30.00 for HROW on 2024-06-21 08:28:00. The adjusted price target was set to $30.00. At the time of the announcement, HROW was trading at $19.93. The overall price target consensus is a...

Harrow Health, Inc. (NASDAQ: HROW) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 13.77% on the day to $20.08. Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an op...

2024-06-20 08:34:14 ET More on Harrow Health Harrow, Inc. 2024 Q1 - Results - Earnings Call Presentation Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript Harrow: Merits A Buy On Sales Potential Harrow Health Non-GAAP EPS of -$0.28 misses by $0.07, revenue...

Successful Manufacture of TRIESENCE PPQ Batch Leads to Scheduling of Remaining Process Qualification Steps, Initial Inventory Build, and Pre-Commercial Activities Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufa...

2024-06-18 23:39:00 ET Summary Investing in individual high yield bonds can outperform high yield bond funds by examining reward to risk. Analyzing current high yield bonds can help identify bonds with the highest reward to risk for superior returns. A list of high yield bonds...